Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use

Author(s):  Teimouri Arezou, Yeung Pollen, Agu Remigius U

Issue:  Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue

Page(s):  482-490

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 1
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 2
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 3
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 4
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 5
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 6
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 7
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 8
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Page 9

Download in electronic PDF format for $75

Abstract:  Interest in the topical use of compounded diltiazem has increased. Published information on the stability of such products is scarce. The objective of this study was to investigate the stability of diltiazem hydrochloride compounded in cream (Glaxal Base), ointment (white petrolatum), and hydroxyethyl cellulose-based gel over 90 days at room (23°C), refrigerator (4°C), and elevated (40°C) temperatures, stored in white plastic and glass amber containers. Organoleptic properties, pH changes, and United States Pharmacopeia recommendations were used for assigning beyond-use-dates. The results showed that the currently recommended United States Pharmacopeia beyond-use date of 30 days is acceptable for diltiazem (2%) in Glaxal Base at 4°C and 23°C in either white plastic or glass amber jars. The cream, however, is not recommended for use if exposed to elevated temperatures (40°C) in white plastic jars but may be used within 7 days if stored in glass amber jars. A beyond-use date of 90 days for diltiazem (2%) hydroxyethyl cellulose-based gel, when maintained at 4°C or 23°C, in either white plastic or glass amber jars, is recommended. Gels exposed to elevated temperatures (40°C) should be used within14 and 30 days in glass amber and white plastic jars, respectively. Lastly, a BUD of 90 days for diltiazem (2%) ointment (white petrolatum) at 23°C stored in either jar type is acceptable. Ointment formulations exposed to elevated temperatures (40°C) may be used within 7 days in white plastic jars. Diltiazem (2%) in white petrolatum should not be stored at 4°C.

Related Keywords: Arezou Teimouri, BSc (Pharm), MSc (Pharm Sci), Pollen Yeung, BSc (Pharm), PhD, Remigius U. Agu, BPharm, MPharm (Pharmacology), MPharm (Pharmaceutics), PhD, diltiazem hydrochloride, topical preparations, calcium channel blocker, chronic anal fissures, diabetic ulcers, stability, storage conditions, commercial bases, temperature

Related Categories: DERMATOLOGY, DIABETES, EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 482-490

Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Jul/Aug 2021
Pg. 344-351

Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 501-508

Stability of Venlafaxine Immediate-Release Suspensions
Donnelly Ronald F
, Wong Keith, Goddard Rob, Johanson Christel
Jan/Feb 2011
Pg. 81-84

Pathophysiology and Management of Onychomycosis and Novel Approaches for Effective Transdermal Applications
Dharmian Jose Prakash
, Sathiyaseelan Iraniammal, Renganathan Akshaya, Mubees Alamaan Mohamed, Naser Mohammed Yasin Abdul, Ramkrishnan Prakash, Arumugam Somasundaram
Nov/Dec 2023
Pg. 494-502

Stability Assessment of Topical Amitriptyline Extemporaneously Compounded with Lipoderm Base, PLO Gel Mediflo 30, and Emollient Cream
Shakshuki Ayah
, Agu Remigius U
Jan/Feb 2019
Pg. 82-87

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah
, Agu Remigius U
Nov/Dec 2019
Pg. 496-503

Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats
Nani Marcel
, Leone Andréia, Bom Vinícius Pedro, Buszinski Andrei Felipe, Oliveira de Souza Rebeca, Pinheiro Vanessa Alves, Danapoulos Panagiota, Swikidisa Rosita, Marquele-Oliveira Franciane, Cipriani Frade Marco Andrey, Berretta Andresa Aparecida, Nogueira Rodrigo José Lupatini
Mar/Apr 2018
Pg. 154-163

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Compounding Solutions for Exotic and Nondomesticated Fauna in Australia: An Investigative Study
Haywood Alison
, Bolitho Richard, Gusti Kane, Yim Crystal, Testa Chris, Hattingh Laetitia
Sep/Oct 2009
Pg. 440-444

Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
May/Jun 2004
Pg. 206-209

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat
, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jan/Feb 2021
Pg. 62-72

Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution
Zaid Abdel-Naser
, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim
Nov/Dec 2021
Pg. 523-527

Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C
, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Jul/Aug 2021
Pg. 336-343

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina
, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
May/Jun 2018
Pg. 247-251

Return to Top